McKesson’s 41% distribution share, specialty-led earnings growth, $5.4 billion free cash flow, and discounted 19.8x forward P/E support a defensive compounder thesis.
Overview
McKesson is a healthcare infrastructure intermediary that distributes pharmaceuticals and medical supplies while monetizing specialty clinical networks and healthcare technology. Its four segments are North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The North American Pharmaceutical business is the dominant revenue engine, while oncology, specialty care, CoverMyMeds, and clinical platforms support better economics. **Scale and embedded infrastructure underpin a durable moat:** McKesson has approximately 41% U.S. pharmaceutical distribution share, while the Big Three control more than 90% of the market. Fiscal 2026 revenue rose 12% to $403.4 billion, adjusted diluted EPS grew 18% to $39.11, operating cash flow was $6.2 billion, and free cash flow was $5.4 billion. Fiscal 2027 adjusted EPS guidance is $43.80–$44.60, or 12%–14% growth. The stock trades at approximately 19.8x forward adjusted P/E versus roughly 24.9x for healthcare. Near-term catalysts include the Medical-Surgical separation, specialty and GLP-1 growth, buybacks authorized up to $7.7 billion, and the July 22, 2026 dividend increase to $0.94 per share. Key risks are CVS renewal in June 2027, thin margins, regulation, and execution.